

REMARKS


The Amendment filed was objected to because there was no complete listing of claims and no underline or deletion to show changes made to the claims. /

Applicant has submitted a complete listing of claims and a copy of the amended claims to show the changes made thereto.

Applicants' undersigned attorney may be reached by telephone at (858) 622-8060. All correspondence should continue to be directed to our address given below. The Commissioner is hereby authorized to charge all fees due, or credit any overpayment, to Deposit Account Number 500329. If any fee not submitted herewith is required for the filing or consideration of this amendment, including a fee for any necessary extension of time, please charge all such required fees to Deposit Account No. 500329.

Respectfully submitted,

Date: December 7, 2004


Karl Neidert
Attorney For Applicant
Registration No. 39,313

Agouron Pharmaceuticals, Inc.
A Pfizer Company
Legal Division, Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: 858/622-8060
Fax: 858/678-8233


Amendments to the Drawings:

None.



Claims marked to show the changes therein:

1 (Amended) A compound of formula I



its enantiomers, diastereomeric or tautomeromic isomers, or a pharmaceutically acceptable salt wherein,

R¹ is

- (a) Cl
- (b) Br
- (c) F, or
- (d) CN;

R² is

- (a) C₁₋₄ alkyl optionally substituted by one or more OH or C₁₋₄ alkoxy, or
- (b) (CH₂)_mOCH₃CH₂OH;

R³ is C₁₋₂ alkyl;

R⁴ is phenyl optionally fused to a benzene or pyridine ring, and substituted with one or more R⁶;

R⁵ is

- (a) H, or
- (b) C₁₋₂ alkyl optionally substituted by OH;

R⁶ is

- (a) halo,
- (b) OCF₃,
- (c) cyano,
- (d) nitro,

- (e) CONR^7R^8 ,
- (f) NR^7R^8 ,
- (g) C_{1-7} alkyl which is optionally partially unsaturated and optionally substituted by one or more R^9 ,
- (h) $\text{O}(\text{CH}_2\text{CH}_2\text{O})_n\text{R}^{10}$,
- (i) OR^{10}
- (j) CO_2R^{10} ,
- (k) phenyl optionally substituted by halo, C_{1-7} alkyl or C_{1-7} alkoxy,
- (l) SR^{10}
- (m) imidazolyl,
- (n) $\text{S}(\text{O})_m\text{NR}^7\text{R}^8$,
- (o) $\text{NHC}(=\text{O})\text{R}^{10}$, or
- (p) any two adjacent R^6 substituents taken together constitute a group of the formula $-\text{O}(\text{CH}_2)_m\text{O}-$, $-(\text{NH})(\text{CO})(\text{CH}_2)_j\text{O}-$, or $-(\text{CH}_2)_i-$;

R^7 and R^8 are independently

- (a) H,
- (b) phenyl optionally substituted by halo, C_{1-7} alkyl or C_{1-7} alkoxy,
- (c) C_{1-7} alkyl which is optionally substituted by one or more OR^{10} , phenyl, or halo substituents
- (d) C_{3-8} cycloalkyl,
- (e) $(\text{C}=\text{O})\text{R}^{11}$,
- (f) R^7 and R^8 together with the nitrogen to which they attach form a het, wherein het is a five- (5), or six- (6) membered heterocycle ring having one (1), two (2), or three (3) heteroatoms selected from the group consisting of oxygen, sulfur or nitrogen, wherein het is optionally substituted with C_{1-4} alkyl;

R^9 is

- (a) oxo,
- (b) phenyl optionally substituted by halo, C_{1-7} alkyl or C_{1-7} alkoxy,
- (c) OR^{10} ,
- (d) $\text{O}(\text{CH}_2\text{CH}_2)\text{OR}^{10}$,

- (e) SR^{10} ,
- (f) NR^7R^8 ,
- (g) halo,
- (h) CO_2R^{10} ,
- (i) $CONR^{10}R^{10}$, or
- (j) C_{3-8} cycloalkyl optionally substituted by OR^{10} ;

R^{10} is

- (a) H,
- (b) C_{1-7} alkyl
- (c) C_{3-8} cycloalkyl or
- (d) phenyl optionally substituted by halo, C_{1-7} alkyl or C_{1-7} alkoxy

R^{11} is

- (a) C_{1-7} alkyl
- (b) C_{3-8} cycloalkyl, or
- (c) Phenyl optionally substituted by halo, C_{1-7} alkyl or C_{1-7} alkoxy;

i is 3 or 4

j is 0 or 1

n is 1, 2, 3, 4, or 5 and

each m is independently 1 or 2.

34. (Amended) A method of treating atherosclerosis and restenosis, mediated by herpesviral infection, comprising administering to a mammal in need thereof a therapeutic amount of a compound of claims 1 or 2.

37. (Amended) A compound of claim 1 which is
~~(1) —N(4-chlorobenzyl)-2-(((2S)-2-hydroxy-2-(4-hydroxyphenyl)ethyl)(methylamino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,~~

~~(2) N-(4-chlorobenzyl)-2-(((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,~~

(3) N-(4-Chlorobenzyl)-7-(2,3-dihydroxypropyl)-2-(((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

(4) N-(4-chlorobenzyl)-2-(((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-7-(3-hydroxypropyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

(5) N-(4-Chlorobenzyl)-7-(2-hydroxyethyl)-2-(((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

(6) N-(4-Chlorobenzyl)-2-(((2S)-2-hydroxy-2-(3-methoxyphenyl)ethyl)(methyl)amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

~~(7) N-(4-Chlorobenzyl)-7-ethyl-2-(((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,~~

(8) N-(4-Chlorobenzyl)-2-(((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-4-oxo-7-propyl-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

(9) N-(4-Chlorobenzyl)-2-(((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-7-(2-methoxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

(10) N-(4-Chlorobenzyl)-2-(((2S)-2-hydroxy-2-(4-cyanophenyl)ethyl)(methyl)amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

(11) N-(4-Chlorobenzyl)-2-(((2S)-2-hydroxy-2-(3-cyanophenyl)ethyl)(methyl)amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

(12) N-(4-Chlorobenzyl)-2-(((2S)-2-(4-(dimethylamino)phenyl)-2-hydroxyethyl)(methyl)amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

(13) N-(4-Chlorobenzyl)-2-(((2S)-2-hydroxy-2-(4-(hydroxymethyl)phenyl)ethyl)(methyl)amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide,

(14) N-(4-Chlorobenzyl)-2-((((2S)-2-hydroxy-2-(4-nitrophenyl)ethyl)(methyl-amino)methyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide, or a pharmaceutically acceptable salt thereof.